Table 1 Clinical profile of the therapy group
Clinical variables | TG |
|---|---|
Histological type | |
Infiltrating ductal carcinoma | 4 (40) |
Invasive lobular | 6 (60) |
Immunohistochemistry | |
ER+ | 5 (50) |
PR+ | 5 (50) |
HER2+ | 1 (10) |
Ki67 <20% | 7 (70) |
Ki67≥20% | 2 (20) |
Molecular subtype | |
Luminal A | 5 (50) |
Luminal B/HER2 | 2 (20) |
Triple negative | 3 (30) |
Staging | |
I | 9 (90) |
II | 1 (10) |
Chemotherapy | |
Neoadjuvant | 6 (60) |
Adjuvant | 4 (40) |
Protocol | |
AC (15 days) + Taxol (Weekly) | 8 (80) |
Taxol (Weekly) + Herceptin (every 21 days) | 2 (20) |